Search
Phenelzine
go.drugbank.com/drugs/DB00780ApprovedInvestigationalPhenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA ap...
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeClocapramine
go.drugbank.com/drugs/DB09003ExperimentalClocapramine has been implicated in at least one strange death, including a suicide. … In addition to psychosis, clocapramine has also been used to augment antidepressants in the treatment of anxiety and panic.
Fenofibric acid
go.drugbank.com/drugs/DB13873ApprovedInvestigationalIt works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol. … [A32038,L12855] Due to its high hydrophilicity and poor absorption profile,[A32038] prodrug ,[fenofibrate], and other conjugated compounds of fenofibric acid, such as choline fenofibrate, have been developed
Cetuximab
go.drugbank.com/drugs/DB00002ApprovedInvestigational[A228083] _In vitro_, cetuximab was shown to mediate anti-tumour effects in numerous cancer cell lines and human tumour xenografts. … Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor
Bendazac
go.drugbank.com/drugs/DB13501ApprovedWithdrawna small handful of regions may continue to have the medication available for purchase and use either as a topical anti-inflammatory/analgesic cream or eye drop formulation. … Bendazac, however, has since been withdrawn or discontinued in various international regions due to its capability or risk for eliciting hepatotoxicity [A39891, A39892, A39893, L4778] in patients although
Zidesamtinib
go.drugbank.com/drugs/DB21623ApprovedInvestigationalZidesamtinib is an orally administered ROS1 kinase inhibitor designed to remain active against ROS1 resistance mutations. … [L63808] The FDA approved zidesamtinib on July 22, 2026, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who received a prior ROS1 kinase inhibitor.
Lomefloxacin
go.drugbank.com/drugs/DB00978ApprovedAdditionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. … Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs).
Cholic Acid
go.drugbank.com/drugs/DB02659ApprovedInvestigational[PubChem] Cholic acid, formulated as Cholbam capsules, is approved by the United States Food and Drug Administration as a treatment for children and adults with bile acid synthesis disorders due to single
Voxilaprevir
go.drugbank.com/drugs/DB12026ApprovedInvestigationalPrior to Vosevi, there were no approved retreatment options for patients who have previously received, and failed, a regimen containing an NS5A inhibitor for treatment of chronic HCV infection. … Notably, Vosevi is approved for use in patients with genotypes 1-6 who have been previously treated with an NS5A inhibitor, or patients with genotypes 1a or 3 infection and have previously been treated
Polythiazide
go.drugbank.com/drugs/DB01324ApprovedA thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826)